177Lu-PSMA-617 offers a new treatment alternative – APCCC

Advanced Prostate Cancer Consensus Conference (APCCC) posted the following on LinkedIn:

“PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer out on The Lancet.

In a phase 3 trial, [177Lu]Lu-PSMA-617 significantly improved radiographic progression-free survival compared to a change in androgen receptor pathway inhibitors (ARPI) in taxane-naive patients with PSMA-positive metastatic castration-resistant Prostate Cancer.

With a median follow-up of 24.1 months, the 177Lu-PSMA-617 group had a median progression-free survival of 11.6 months versus 5.6 months in the ARPI change group. The safety profile of 177Lu-PSMA-617 was favorable, showing fewer severe adverse events compared to the ARPI change group.

These results suggest that 177Lu-PSMA-617 could be an effective treatment alternative for patients who have progressed on prior ARPI therapy.”

¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Authors: Prof Michael J Morris, Daniel Castellano, Prof Ken Herrmann, Prof Johann S de Bono, Neal D Shore, Prof Kim N Chi, Michael Crosby, Josep M Piulats, Aude Fléchon, Xiao X Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, Prof James Nagarajah, Begoña Mellado, Álvaro Montesa-Pino, Euloge Kpamegan, Samson Ghebremariam, Teri N Kreisl, Celine Wilke, Katja Lehnhoff, Prof Oliver Sartor, Prof Karim Fizazi, for the PSMAfore Investigators

Source: Advanced Prostate Cancer Center/LinkedIn